Assessment of safety of additional transplantation of autologous bone marrow mononuclear cells in the combined treatment of coronary heart disease. Results from a randomized, blind, placebo-controlled trial (TAMIS)

Assessment of safety of additional transplantation of autologous bone marrow mononuclear cells in the combined treatment of coronary heart disease. Results from a randomized, blind, placebo-controlled trial (TAMIS)

Aim: to assess the safety of transplantation of autologous bone marrow mononuclear cells when performing coronary artery bypass grafting in the combined treatment of ischemic heart disease in patients with coronary and heart failure.Materials and methods. During the period from 2013 to 2016 years 11...

Full description

Bibliographic Details
Main Authors: V. V. Komok, N. S. Bunenkov, S. A. Beliy, V. M. Pizin, V. M. Kondratev, А. V. Dulaev, V. I. Lukashenko, A. E. Kobak, T. S. Maksimova, I. P. Sergienko, E. V. Parusova, L. A. Smirnova, E. V. Babenko, B. V. Afanasev, A. S. Nemkov, G. G. Khubulava
Format: Article
Language:Russian
Published: Federal Research Center of Transplantology and Artificial Organs named after V.I.Shumakov 2019-07-01
Series:Vestnik Transplantologii i Iskusstvennyh Organov
Subjects:
coronary artery bypass grafting
autologous bone marrow mononuclear cells
reperfusion myocardial damage
ischemic heart disease
diastolic dysfunction of the left ventricular myocardium
heart failure
clinical study
Online Access:https://journal.transpl.ru/vtio/article/view/1027

Internet

https://journal.transpl.ru/vtio/article/view/1027

Similar Items